Evidence map›Paper›PMID 27726383›Full record

ReviewChemical research in toxicology2016

Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology.

Heather A Enright, Michael A Malfatti, Maike Zimmermann, Ted Ognibene, Paul Henderson, Kenneth W Turteltaub

Abstract readReview
In one paragraph

Review in Chemical research in toxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Identification and Quantitation ofMethods and protocols · 2025
    Article
  4. Article
  5. HPLC-Parallel accelerator and molecular mass spectrometry analysis ofJournal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2023
    Article
  6. Review
  7. Article
  8. Direct Carbon Isotope Exchange through Decarboxylative Carboxylation.Journal of the American Chemical Society · 2019
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Heather A Enright
Michael A Malfatti
Maike ZimmermannDepartment of Internal Medicine, Division of Hematology and Oncology, UC Davis Medical Center , Sacramento, California 95817, United States.
Ted Ognibene
Paul HendersonDepartment of Internal Medicine, Division of Hematology and Oncology, UC Davis Medical Center , Sacramento, California 95817, United States.
Kenneth W Turteltaub

Funding

Resource for the Development of Biomedical Accelerator Mass Spectrometry (AMS)P41GM103483 · NIGMS · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · PI TURTELTAUB, KENNETH W. · 2012 to 2019
$12.0M
NCI NIH HHS HHSN261201000133CNCI NIH HHS HHSN261201200048CNCI NIH HHS HHSN261201200084CNIGMS NIH HHS P41 GM103483
6 · The paper itself

Abstract

Accelerator mass spectrometry (AMS) has been adopted as a powerful bioanalytical method for human studies in the areas of pharmacology and toxicology. The exquisite sensitivity (10

Indexed as

ToxicologyHumansMass Spectrometry

Identifiers

PMID27726383
PMCPMC5203773

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.